Business Context and Reporting Period
This Form 8-K filing by LeMaitre Vascular, Inc. covers the reporting period of September 17, 2008. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to restore compliance with Nasdaq Marketplace Rules following the resignation of an independent director in July 2008.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation policies:
- Annual Retainer (Board Membership): $10,000
- Annual Retainer (Audit Committee Chair): $15,000
- Total Annual Retainer for Mr. O'Connor: $25,000
- Meeting Fees: $2,500 per in-person Board meeting; $1,000 per telephonic/video Board meeting; $500 per special or committee meeting.
- Compensation Cap: $40,000 per calendar year without specific Board approval.
- Stock Options: 20,000 shares upon initial appointment; 7,500 shares annually thereafter (subject to service requirements).
Material Changes
The material change reported is the appointment of John J. O'Connor as a Class III Director and Chair of the Audit Committee, effective September 17, 2008. This appointment was necessitated by the voluntary resignation of independent director David N. Gill in July 2008, which had caused the Company to fall out of compliance with Nasdaq rules requiring a majority of independent directors and a three-member independent Audit Committee.
Outlook, Risks, and Management Commentary
Management expects that the appointment of Mr. O'Connor will allow the Company to regain compliance with Nasdaq Marketplace Rules 4350(c)(1) and 4350(d)(2). The filing notes that Nasdaq rules permit filling such vacancies within one year of the event causing the vacancy or by the next annual shareholders' meeting, whichever is earlier. The Company anticipates that Nasdaq will confirm compliance upon review. No other risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the Company's current status regarding Nasdaq compliance following this appointment.
- Confirm the vesting schedule and exercise terms of the 20,000 stock options granted to Mr. O'Connor.
- Review the Company's 2006 Stock Option and Incentive Plan for details on potential adjustments to the granted shares.
- Check subsequent filings for confirmation of the Company's regained compliance status with Nasdaq.